RT Journal Article
SR Electronic
T1 Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.26.21262579
DO 10.1101/2021.08.26.21262579
A1 Mary Bushman
A1 Rebecca Kahn
A1 Bradford P. Taylor
A1 Marc Lipsitch
A1 William P. Hanage
YR 2021
UL http://medrxiv.org/content/early/2021/08/29/2021.08.26.21262579.abstract
AB SARS-CoV-2 variants of concern exhibit varying degrees of transmissibility and, in some cases, escape from infection- and vaccine-induced immunity. Much effort has been devoted to measuring these phenotypes, but predicting their impact on the course of the pandemic – especially that of immune escape – remains a challenge. Here, we use a mathematical model to simulate the dynamics of wildtype and variant strains of SARS-CoV-2 in the context of vaccine rollout and nonpharmaceutical interventions. We show that variants with enhanced transmissibility easily rise to high frequency, whereas partial immune escape, on its own, often fails to do so. However, when these phenotypes are combined, enhanced transmissibility can carry the variant to high frequency, at which point partial immune escape may limit the ability of vaccination to control the epidemic. Our findings suggest that moderate immune escape poses a low risk unless combined with a substantial increase in transmissibility.Competing Interest StatementRK discloses consulting fees from Partners In Health and the Pan American Health Organization. ML received funding through his institution from US CDC, NIH, and UK National Institute for Health Research, and Pfizer, and consulting fees or honoraria from Merck, Sanofi Pasteur, Janssen, and Bristol Myers Squibb. He is a member of the Scientific Advisory Board for CEPI, the Coalition for Epidemic Preparedness Innovations. WPH serves on the Advisory Board of Biobot Analytics and has received compensation for expert witness testimony on the course of the SARS-CoV-2 pandemic.Funding StatementMB and BPT were supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number R01AI128344. RK, ML and WPH were supported by the U.S. National Cancer Institute SeroNet cooperative agreement U01CA261277.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesModel code is freely available at https://osf.io/z9x2p/?view_only=6def9d71316645d0a54a30fa6e9ffe13